RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Rocket Pharmaceuticals, Inc. (RCKT) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Momentum (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | C+ (2.5) | C- (2.1) | D+ (1.8) | A+ (5.0) | C+ (2.8) |
| 2026-11-07 | C+ (2.5) | C+ (2.5) | C+ (2.7) | D+ (1.8) | A+ (5.0) | B- (2.9) |
| 2026-10-31 | C+ (2.5) | C+ (2.5) | C+ (2.7) | D+ (1.8) | A+ (5.0) | B- (2.9) |
| 2026-10-24 | B+ (3.7) | C+ (2.5) | C+ (2.7) | D+ (1.7) | A+ (5.0) | B- (3.1) |
| 2026-10-17 | B+ (3.7) | C+ (2.5) | C+ (2.7) | C- (1.9) | A+ (5.0) | B (3.2) |